Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 17.15 USD 3.75%
Market Cap: 2.2B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Neogenomics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Neogenomics Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Neogenomics Inc
NASDAQ:NEO
Total Current Liabilities
$296.4m
CAGR 3-Years
47%
CAGR 5-Years
34%
CAGR 10-Years
36%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Current Liabilities
$14.6B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Current Liabilities
$7.3B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Total Current Liabilities
$1.2B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Total Current Liabilities
$1.9B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Total Current Liabilities
$7B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.2B USD
Industry
Life Sciences Tools & Services

NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine. By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.

NEO Intrinsic Value
12.37 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Neogenomics Inc's Total Current Liabilities?
Total Current Liabilities
296.4m USD

Based on the financial report for Sep 30, 2024, Neogenomics Inc's Total Current Liabilities amounts to 296.4m USD.

What is Neogenomics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
36%

Over the last year, the Total Current Liabilities growth was 219%. The average annual Total Current Liabilities growth rates for Neogenomics Inc have been 47% over the past three years , 34% over the past five years , and 36% over the past ten years .

Back to Top